GSK reports promising early results in ovarian and womb cancer drug trial
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, steps